Amwell Reports Q3 Revenue Above Guidance, Issues Q4 Outlook
Amwell reported third-quarter revenue of $49.0 million, exceeding its previously provided guidance range. Net loss was $11.0 million, versus $9.6 million in Q2, and adjusted EBITDA was negative $3.6 million. For Q4 2026, Amwell projects revenue of $48 million to $50 million and adjusted EBITDA of $0 million to $1 million.
Amwell reported total revenue of $49.0 million for the third quarter ended September 30, 2026, exceeding its previously provided guidance range. The company recorded subscription revenue of $23.9 million and Amwell Medical Group visit revenue of $23.7 million, with a total of 0.8 million platform visits. The net loss for the quarter was $11.0 million, compared to $9.6 million in the second quarter of 2026, while adjusted EBITDA was negative $3.6 million. Looking ahead, Amwell provided fourth-quarter 2026 financial guidance, projecting revenue between $48 million and $50 million and adjusted EBITDA in the range of $0 million to $1 million.